Allied Biotech Corporation (1780) Fair Value & Analysis
Healthcare · TW · Market cap 2.5B TWD
Fair value as of: Jul 23, 2026
From 24 valuation models · updated 18 days ago
Fair value updated Jul 23, 2026, revised from 22.87 TWD to 20.18 TWD (−11.8%) since Jul 7, 2026. Share price −6.1% over the past month.
A solid business, but screening 13% overvalued on our models.
What matters now
- Our model range runs from 15.13 TWD (bear) to 25.22 TWD (bull), base 20.18 TWD. The closer the price sits to the lower half, the larger the margin of safety.
- Quality 74/100 (solid quality) with high evidence: the data supports the verdict.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 23, 2026.
How to read this chart
60‑month range 10.44 TWD – 34.64 TWD · fair‑value band 15.13 TWD – 25.22 TWD · the 23.20 TWD price screens above the 20.18 TWD fair value. Dashed = 300-day average. As of Jul 23, 2026.
Analysis
Allied Biotech Corporation (1780) currently trades at 23.20 TWD, while our model-based Fair Value estimate is 20.18 TWD, implying the stock looks roughly 13.0% overvalued today. The Quality Score stands at 74/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, Allied Biotech Corporation generated revenue of 850M TWD at a net margin of 15.2%. Revenue grew 14.9% year over year. It earns a return on equity of 10.7%. The balance sheet holds a net cash position of 23.0M TWD. Fundamentals as of Jul 23, 2026
Our scenario range runs from 15.13 TWD (bear case) to 25.22 TWD (bull case); at 23.20 TWD, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 35% below its 52-week high and 44% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -49% fair-value upside, at -13%, 1780 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 24 models by family
Widest divergence: DCF Models (30.11 TWD) versus Earnings-Based (6.40 TWD). Highest evidence: Growth DCF (80).
Notify me when 1780 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 23, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 73 · Market factors (momentum, volatility) 53
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Allied Biotech Corporation engages in the manufacture and sale of carotenoids worldwide. The company's products include Beta-Carotene that offers yellow to reddish orange shades to appeal color in various applications; Beta-Apo-8'-Carotenal, which is used as a food colorant, and provides a range of orange to red shades; and Lycopene, which offers a range of …
Full company description
Allied Biotech Corporation engages in the manufacture and sale of carotenoids worldwide. The company's products include Beta-Carotene that offers yellow to reddish orange shades to appeal color in various applications; Beta-Apo-8'-Carotenal, which is used as a food colorant, and provides a range of orange to red shades; and Lycopene, which offers a range of red shades as a nutrient for food, dietary supplements, and pharmaceutical products. It also provides Canthaxanthin, which offers a range of shades of reddish orange for food and beverage applications; Lutein, a carotenoid that provides a range of green leafed vegetables, such as spinach, kale, broccoli, and egg yolks.; and Nano Coenzyme Q10, an antioxidant, which is used in the transformation of energy in the body. It serves food, beverage, dietary supplement, and feed industries. The company was founded in 2001 and is headquartered in Taipei, Taiwan.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Allied Biotech Corporation reported revenue of 850M TWD in FY2025 versus 677M TWD in FY2021, a compound +5.8%/yr. Reported net income was 129M TWD in FY2025, compounding +77.5%/yr from FY2021.
of which total revenue +4.7 pp · buybacks/dilution −0.2 pp
Absolute contributions in percentage points per year; they sum to the EPS growth rate. Start and end points are 3-year averages (details on hover).
1780 screens 13% overvalued. Compare with Jiangsu Hengrui Pharmaceuticals Co →
Peer Group
Drug Manufacturers - Specialty & Generic · 623 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Drug Manufacturers - Specialty & Generic median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 23, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥53.19 | ¥25.94 | -51% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,933 | ₹989.50 | -49% |
| Divi's Laboratories Limited DIVISLAB | ₹7,316 | ₹1,943 | -73% |
| Torrent Pharmaceuticals Limited TORNTPHARM | ₹4,763 | ₹1,329 | -72% |
| PharmaEssentia Corporation 6446 | 1,285 TWD | 221.01 TWD | -83% |
| Cipla Limited CIPLA | ₹1,439 | ₹1,001 | -30% |
| Zydus Lifesciences Limited ZYDUSLIFE | ₹1,151 | ₹703.32 | -39% |
| Lupin Limited LUPIN | ₹2,443 | ₹2,477 | +1% |
| Mankind Pharma Limited MANKIND | ₹2,484 | ₹983.11 | -60% |
| Dr. Reddy's Laboratories Limited DRREDDY | ₹1,211 | ₹874.79 | -28% |
Compare Allied Biotech Corporation with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Allied Biotech Corporation (1780) overvalued or undervalued?
What is the fair value of 1780?
What is the quality score of 1780?
What is the revenue of Allied Biotech Corporation (1780)?
What is the net profit margin of 1780?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Allied Biotech Corporation and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.